TNYA Live signals | Maximize Profits with Getagraph.com

SELL 92567 min ago

@ $5.35

Issued: 14 Feb 2024 @ 09:30

Return: -19.81%

Previous signal: Feb 12 - 11:24

Previous signal: Buy

Return: -6.14 %

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	281 683
Average Volume	624 558
Market Cap	336.83M
EPS	$-0.390 ( 2024-03-20 )
Next earnings date	( $-0.430 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.55
ATR14	$0.0120 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-05	Hoey Timothy	Sell	3 300	Common Stock
2024-02-23	Hoey Timothy	Buy	12 500	Common Stock
2024-02-23	Hoey Timothy	Buy	75 000	Stock Option (Right to buy)
2024-02-23	Tingley Whittemore	Buy	215 000	Stock Option (Right to buy)
2024-02-23	Tingley Whittemore	Buy	35 000	Common Stock

INSIDER POWER
99.37
Last 96 transactions
Buy: 62 840 535 \| Sell: 9 767 330

Volume Correlation

Long: 0.32 (neutral)

Short: 0.07 (neutral)

Signal:(63.362) Neutral

Tenaya Therapeutics, Inc. Correlation

10 Most Positive Correlations
MDRR	0.829
RESN	0.81

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tenaya Therapeutics, Inc. Correlation - Currency/Commodity

0.16
( neutral )

0.12
( neutral )

0.00
( neutral )

0.01
( neutral )

0.00
( neutral )

-0.09
( neutral )

Tenaya Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-8.69M (0.00 %)
EPS:	$-1.680

Q4	2023
Revenue:	$0
Gross Profit:	$-2.99M (0.00 %)
EPS:	$-0.440

Q3	2023
Revenue:	$0
Gross Profit:	$-2.98M (0.00 %)
EPS:	$-0.390

Q2	2023
Revenue:	$0
Gross Profit:	$-2.97M (0.00 %)
EPS:	$-0.450

Financial Reports:

No articles found.

Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.